Tag: Alladapt Immunotherapeutics
FDA Fast Tracks Alladapt’s ADP101 for the Treatment of Single and...
Fast Track Designation accelerates ADP101's development path for the treatment of food allergies.
Alladapt’s Multi-Allergen OIT Candidate Shows Promise in Clinical Study
Company will begin Phase 3 study in 2024.
Alladapt Announces Positive Results for Multi-Allergen OIT Candidate from Phase 1/2...
OIT candidate treats allergies to the Top 9 allergens at the same time.
Alladapt’s 15-Allergen OIT Candidate Ready to Begin Phase 1/2 Study
ADP101 is intended to treat patients with an allergy to one or more of peanut, almond, hazelnut, cashew, pistachio, pecan, walnut, milk, egg, cod, salmon, shrimp, wheat, soy, and sesame.
Alladapt Enrolling Participants for Clinical Study of OIT Therapy to Treat...
The study is still seeking participants 4-55 years of age.
Broad Spectrum OIT Candidate for Multiple Food Allergies Begins Phase 1/2...
The Harmony Study plans to enroll patients across 20 sites in the United States.
Alladapt Immunotherapeutics Secures $60 Million in Series C Financing for Development...
Company is developing therapy to target a number of food allergies simultaneously.
